Skip to main content

Table 3 Details on inpatients’ length of stay. Percentages are rounded and are for guidance only

From: Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data

Cohort

Patients

n (%)

LOS mean

(sd) [HD]

LOS mean (PCI) [HD]

Inpatients

94 (100)

20 (28)

Started OI and maintained OI

27 (29)

12 (13)

(8 ; 18)

Started CT-P13 and maintained CT-P13

22 (23)

31 (41)

(17 ; 50)

Started OI and discontinued OI

6 (6)

8 (5)

(4 ; 12)

Started CT-P13 and discontinued CT-P13

21 (22)

23 (26)

(13 ; 35)

Switched from OI to CT-P13 and maintained CT-P13

8 (9)

8 (13)

(2 ; 17)

Switched from OI to CT-P13 and discontinued CT-P13

7 (7)

12 (12)

(4 ; 21)

Switched from OI to CT-P13 and switched back to OI

3 (3)

62 (42)

(15 ; 95)

  1. HD Hospital day, LOS Length of stay, OI Originator infliximab, PCI Percentile confidence intervals, sd standard deviation